Traditional and non traditional risk factors in accelerated atherosclerosis in Systemic Lupus Erythematosus: Role of vascular endothelial growth factor (VEGATS Study)

Autoimmunity Reviews

Volumn 8, Issue 4, 2009, Pages 309-315

  Colombo, Barbara Maria ^a   Cacciapaglia, Fabio ^b   Puntoni, Matteo ^c   Murdaca, Giuseppe ^a   Rossi, Edoardo ^d   Rodriguez, Guido ^c   Nobili, Flavio ^c   Pisciotta, Livia ^a   Bertolini, Stefano ^a   Moccetti, Tiziano ^e   Dentali, Francesco ^f   Steidl, Luigi ^f   Ciprandi, Giorgio ^a   Afeltra, Antonella ^b   Indiveri, Francesco ^a   Puppo, Francesco ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e DIVISION OF CARDIOLOGY   (Switzerland)

^f OSPEDALE DI CIRCOLO   (Italy)

Author keywords

Atherosclerosis; Intima media thickness (IMT); Systemic Lupus Erythematosus (SLE); Vascular endothelial growth factor (VEGF)

Indexed keywords

VASCULOTROPIN;

ADULT; AGE DISTRIBUTION; AGED; ARTERIAL WALL THICKNESS; ATHEROGENESIS; ATHEROSCLEROSIS; B SCAN; CARDIOVASCULAR RISK; CAROTID ARTERY; CONTROLLED STUDY; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; PHYSICAL EXAMINATION; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; SMOKING HABIT; STRUCTURED INTERVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; ATHEROSCLEROSIS; CAROTID ARTERIES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; INTERVIEWS AS TOPIC; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RISK FACTORS; TUNICA INTIMA; TUNICA MEDIA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 61349192714     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2008.10.002     Document Type: Review

References (40)

1. Ward M.M. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 42 (1999) 338-346
2. Manzi S., and Wasko M. Inflammation-mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis 59 (2000) 321-325
3. Petri M., Perez-Gutthann S., Spence D., and Hochberg M.C. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 93 (1992) 513-519
4. Petri M., Roubenoff R., Dallal G.E., Nadeau M.R., Selhub J., and Rosenberg I.H. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 348 (1996) 1120-1124
5. Jara L.J., Medina G., Vera-Lastra O., and Amigo M.C. Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases. Autoimmun Rev 5 (2006) 195-201
6. Asanuma Y., Oeser A., Shintani A.K., et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 349 (2003) 2407-2415
7. Manzi S., Meilahn E.N., Rairie J.E., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145 (1997) 408-415
8. Urowitz M.B., Bookman A.A.M., Koehler B.E., Gordon D.A., Smythe H.A., and Ogryzlo M.A. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 60 (1976) 221-225
9. Abou-Raya A., and Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 5 (2006) 331-337
10. Esdaile J.M., Abrahamowicz M., Grodzicky T., et al. Traditional risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44 (2001) 2331-2337
11. Petri M., Perez-Gutthann S., Spence D., and Hochberg M.C. Risk factors for coronay artery disease in patients with systemic lupus erythematosus. Am J Med 93 (1992) 513-519
12. Petri M., Spence D., Bone L.R., and Hochberg M.C. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) 71 (1992) 291-302
13. Roman M.J., Shanker B.A., Davis A., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349 (2003) 2399-2406
14. Doria A., Arienti S., Rampudda M., Canova M., Tonon M., and Sarzi-Puttini P. Preventive strategies in systemic lupus erythematosus. Autoimmun Rev 7 (2008) 192-197
15. Salonen J.T., and Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 87 3 Suppl (1993) II-56-II-65
16. Gnasso A., Irace C., Mattioli P.L., et al. Carotid intima-media thickness and coronary heart disease risk factors. Atherosclerosis 119 (1996) 7-15
17. Crouse J.R., Goldbourt U., Evans G., et al. Risk factors and segment-specific carotid arterial enlargement in the Atherosclerosis Risk in Communities (ARIC) Cohort. Stroke 27 (1996) 69-75
18. O'Leary D.H., Polak J.F., Kronmal R.A., et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340 (1999) 14-22
19. Carvalho J.F., Blank M., and Shgoenfeld Y. Vascular endothelial growth factor (VEGF) in autoimmune diseases. J Clin Immunol 27 (2007) 246-256
20. Inoue M., Itoh H., Ueda M., et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 98 (1998) 2108-2116
21. Tan E.M., Cohen A.S., Fries J.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25 (1982) 1271-1277
22. Bombardier C., Gladman D.D., Urowitz M.B., Caron D., and Chang C.H. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35 (1992) 630-640
23. Sidhu P.S., and Desai S.R. A simple and reproducible method for assessing intimal-medial thickness of the common carotid artery. Br J Radiol 70 (1997) 85-89
24. Webb N.J., Bottomley M.J., Watson C.J., and Brenchley P.E. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond) 94 (1998) 395-404
25. Wynendaele W., Derua R., Hoylaerts M.F., et al. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo. Ann Oncol 10 (1999) 965-971
26. Hormbrey E., Gillespie P., Turner K., Han C., Roberts A., McGrouther D., and Harris A.L. A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful. Clin Exp Metastasis 19 (2002) 651-663
27. Frostegard J. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 25 (2005) 1776-1785
28. Svenungsson E., Jensen-Urstad K., Heimburger M., et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104 (2001) 1887-1893
29. Kuryliszyn-Moskal A., Klimiuk P.A., Sierakowski S., and Ciolkiewicz M. Vascular endotherlial growth factor in systemic lupus erythematosus: relationship to disease activity, systemic organ manifestation and nailfold capillaroscopic abnormalities. Arch Immunol Ther Exp 55 (2007) 179-185
30. Robak E., Sysa-Jedrejowska A., and Robak T. Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with Systemic Lupus Erythematosus. Mediat Inflamm 12 (2003) 293-298
31. Robak E., Wozniacka A., Sysa-Jedrejowska A., Stepien H., and Robak T. Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus. Lupus 11 (2002) 348-355
32. Navarro C., Candia-Zuniga L., Silveira L.H., et al. Vascular endothelial growth factor plasma levels in patients with Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome. Lupus 11 (2002) 21-24
33. Ylä-Herttuala S., Rissanen T.T., Vajanto I., and Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 49 (2007) 1015-1026
34. Kimura K., Hashiguchi T., Deguchi T., Horinouchi S., Uto T., et al. Serum VEGF-As a prognostic factor of atherosclerosis. Atherosclerosis 194 (2007) 182-188
35. Nakajima K., Tabata S., Yamashita T., Kusuhara M., Arakawa K., Ohmori R., et al. Plasma vascular endothelial growth factor level is elevated in patients with multivessel coronary artery disease. Clin Cardiol 27 (2004) 281-286
36. Alber H.F., Frick M., Dulak J., et al. Vascular endothelial growth factor (VEGF) plasma concentrations in coronary artery disease. Heart 91 (2005) 365-366
37. Wong C.K., Lit L.C.W., Tam L.S., Li E.K.M., Wong P.T.Y., and Lam C.W.K. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 127 (2008) 385-393
38. Wong C.K., Ho C.Y., Li E.K., and Lam C.W.K. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 9 (2000) 589-593
39. Honorati M.C., Cattini L., and Facchini A. IL-17, IL-1β and TNF-α stimulate VEGF production by dedifferentiated chondrocytes. Osteoarthr Cartil 12 (2004) 683-691
40. Takahashi H., Numasaki M., Lotzeb M.T., and Sasaki H. Interleukin-17 enhances βFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol Lett 98 (2005) 189-193